Satellos Bioscience prices $50-million (U.S.) offering
Executive Summary
- Satellos Bioscience Inc. priced a $50 million public offering of 4,455,445 common shares and pre‑financed warrants for 495,049 common shares at US$10.10 per share (US$10.09999 per warrant).
- The underwriters received a 30‑day option to purchase up to an additional 742,574 common shares at the offering price.
- Net proceeds are intended to fund R&D—including advancement of SAT‑3247 through Phase 2/3 trials—working capital and general corporate purposes.
Key Details
- Offering Size & Pricing
- 4,455,445 common shares @ US$10.10 per share (CAD $13.81).
-
Prefinanced warrants for 495,049 common shares @ US$10.09999 per warrant (CAD $13.80999), exercisable at a nominal CAD 0.001 per share and without expiration.
-
Underwriter Option
-
30‑day option to purchase up to an additional 742,574 common shares at the same public offering price, less underwriting discounts and commissions.
-
Book‑Running Managers
- Joint book‑runners: Leerink Partners, Guggenheim Securities, Oppenheimer & Co.
-
Co‑manager: Bloom Burton Securities Inc.
-
Gross Proceeds
-
Expected aggregate gross proceeds of approximately US$50 million before underwriting discounts, commissions and other offering expenses.
-
Closing
-
Anticipated closing date: February 9, 2026, subject to customary conditions and required approvals from the Toronto Stock Exchange and Nasdaq Global Market.
-
Use of Proceeds
- Primarily to finance continuing research & development activities, working capital, and general corporate purposes.
-
May include advancing SAT‑3247 through Phase 2–Phase 3 clinical trials (including additional indications) and investment in other discovery‑stage or preclinical programs targeting dystrophies.
-
Listing & Trading
- Common shares to begin trading on Nasdaq under ticker “MSLE” as of the announcement date.
-
Shares also listed on Toronto Stock Exchange under symbol “MSCL”.
-
Related Party Purchases
- Board members Franklin Berger (24,750 shares) and Mark Nawacki (30,000 shares) purchased common shares in the offering.
-
Transactions qualify as related‑party exemptions because total value is < 25 % of market capitalization; material change report timing constrained by short interval to closing.
-
Regulatory Filings
- Offering made pursuant to a prospectus supplement to the company’s short‑form base shelf prospectus dated Oct. 29, 2025 (Canada) and a Form F‑10 registration statement (U.S.).
- Supplement and base prospectus available on SEDAR+, EDGAR and the company website within two business days of the announcement.
Notable Quotes
No direct quotes were provided in the release.